You just read:

Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain

News provided by

Convergence Pharmaceuticals Ltd

18 Jul, 2012, 09:00 BST